Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.

Blood. 2016 Jul 7;128(1):e1-9. doi: 10.1182/blood-2015-11-683334.

2.

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.

Patnaik MM, Tefferi A.

Blood Cancer J. 2016 Feb 5;6:e393. doi: 10.1038/bcj.2016.5. Review.

3.

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, Sargin D.

J Blood Med. 2015 Jun 1;6:157-75. doi: 10.2147/JBM.S78826.

4.

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.

Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z.

Exp Hematol Oncol. 2015 May 20;4:14. doi: 10.1186/s40164-015-0009-y.

5.

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata KC, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine RL, Abdel-Wahab O, Kitamura T.

J Clin Invest. 2013 Nov;123(11):4627-40.

6.

Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

West RR, Hsu AP, Holland SM, Cuellar-Rodriguez J, Hickstein DD.

Haematologica. 2014 Feb;99(2):276-81. doi: 10.3324/haematol.2013.090217.

7.

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T.

Blood Cancer J. 2011 Mar 4;1:e7. doi: 10.1038/bcj.2011.4.

8.

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV.

PLoS One. 2012;7(8):e43090. doi: 10.1371/journal.pone.0043090.

9.

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D.

J Hematol Oncol. 2012 Mar 21;5:12. doi: 10.1186/1756-8722-5-12. Review.

10.

CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Aranaz P, Hurtado C, Erquiaga I, Miguéliz I, Ormazábal C, Cristobal I, García-Delgado M, Novo FJ, Vizmanos JL.

Haematologica. 2012 Aug;97(8):1234-41. doi: 10.3324/haematol.2011.052605.

11.

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA, Zeilemakers A, Löwenberg B, Valk PJ.

Haematologica. 2012 Mar;97(3):388-92. doi: 10.3324/haematol.2011.051532.

12.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

Blood. 2011 Dec 22;118(26):6920-9. doi: 10.1182/blood-2011-08-368225.

13.

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP.

Blood. 2011 Oct 6;118(14):3932-41. doi: 10.1182/blood-2010-10-311019.

14.

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.

Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591.

Items per page

Supplemental Content

Support Center